[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
[ Tue, Feb 21st 2023 ]: WOPRAI
Do Kim Maintained (TVTX) at Buy with Increased Target to $46 on, Feb 21st, 2023
- 🞛 This publication is a summary or evaluation of another publication
Do Kim of Piper Sandler, Maintained "Travere Therapeutics, Inc." (TVTX) at Buy with Increased Target from $42 to $46 on, Feb 21st, 2023.
Do has made no other calls on TVTX in the last 4 months.
There are 2 other peers that have a rating on TVTX. Out of the 2 peers that are also analyzing TVTX, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alex Thompson of "Stifel" Initiated at Hold and Held Target at $22 on, Wednesday, December 14th, 2022
This is the rating of the analyst that currently disagrees with Do
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, January 30th, 2023